New Data from Vasogen's ACCLAIM Trial in Heart Failure Presented at World Congress of Cardiology 2006.

- 31% Risk Reduction in Combined Group of Class III/IV Patients with No Prior Heart Attack and All Class II Patients -

- New Data Define Prime Target Population for Commercial Development -

MISSISSAUGA, ON, Sept. 5 /PRNewswire-FirstCall/ -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that new data from the 2,400-patient ACCLAIM trial in chronic heart failure showed that in a major combined subgroup of New York Heart Association (NYHA) Class III/IV patients with no prior history of heart attack and all Class II patients, together comprising more than 50% of the study population, Vasogen's Celacade(TM) technology reduced the risk of death and cardiovascular hospitalization by 31% (n=1,305 patients, p=0.0003). Celacade was also shown to be safe and well tolerated. The results were presented today by Guillermo Torre-Amione MD, PhD, at a late breaking clinical trial Hot Line Session of the World Congress of Cardiology 2006 in Barcelona, Spain.

"The ACCLAIM results provide compelling evidence that Celacade significantly reduces the risk of death and cardiovascular hospitalization in an important group of heart failure patients that remain underserved by available therapies," stated Dr. Torre-Amione, Medical Director, Heart Transplant Program, Methodist DeBakey Heart Center at The Methodist Hospital, and Principal Investigator for the U.S. arm of the ACCLAIM trial. "These findings are consistent with the role that chronic inflammation plays in the development and progression of heart failure and are particularly impressive in the large subgroup of NYHA Class III/IV patients who had not experienced a prior heart attack and in all NYHA Class II patients. These results provide a strong basis for targeting Celacade's novel anti-inflammatory mechanism in this large and well-defined patient population."

As previously reported, the difference in time to death or first…